1Head of Department of Pharmacognosy and Phytochemistry, IIMT College of Medical Sciences, Meerut, (U.P.) India
2Head, Department of Pharmacognosy, Shri S. K. Patel College of Pharmaceutical Education and Research, Kherva-382711, Gujarat, India
3Director (Pharmacy), IIMT College of Medical Sciences, Meerut, (U.P.) India
*Corresponding Author: Dr. Preeti Tiwari, Head of Department of Pharmacognosy and Phytochemistry, IIMT College of Medical Sciences, Meerut, (U.P.) India. Email: preetitiwari198311@yahoo.com
Online published on 31 October, 2013.
The objective of the present study was to evaluate the effect of Drakshasava-T and Drakshasava-M prepared by traditional and modern methods respectively and marketed Drakshasava on fasting blood glucose and serum lipid profile in alloxan induced diabetic rats. Oral administration of Drakshasava-T, Drakshasava-M and marketed Drakshasava (2 ml/kg p.o.) for 21 days caused a significant decrease in fasting blood glucose (FBG) and showed significant rise in blood glutathione level (GSH) in diabetic rats. Glibenclamide was used as a standard antidiabetic drug (10 mg/kg, p.o). These preparations also caused significant reduction in serum cholesterol, LDL and triglycerides and showed significant rise in serum HDL level in diabetic albino rats. Thus all these preparations were able to maintain the tested parameters near to the normal level significantly.
Cardiovascular risk, Blood glucose, anti-diabetic potential, glutathione, lipid profile, Drakshasava, alloxan
